Sotac Pharmaceuticals share price
NSE: SOTACPharmaceuticals & Biotechnology
Sotac Pharmaceuticals Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Apr 2023 · Issue price ₹111
Last close ₹101.30up ₹4.80 (4.97%)
Share price at the NSE close on 28 Oct 2026. Previous close ₹96.50.
28 Oct: open ₹101.25, high ₹101.30, low ₹101.25
52-week range of traded prices to 28 Oct 2026
₹86.00Low, 31 Jul 2026₹139.65High, 28 Nov 2025
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. Market capitalisation: how it is worked out
- ₹112 Cr
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 19.41
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 1.90
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.20%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 10.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.58
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 2,400100.0% delivered
Results
Consolidated; ₹ crore.Sotac Pharmaceuticals half-yearly results
- Revenue growth, 12 monthsRevenue growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +0.1%
- Net profit growth, 12 monthsNet profit growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- −28.2%
Half year to Mar 2026, against the half year before
- Revenue
- ₹60 Cr
- Net profitNet profit. The pill is the change in net profit against the half year before: this period's figure divided by that one's, less one, in per cent. Net profit in the glossary
- ₹3.32 Crup 35.77%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 5.5%
Revenue by half year
Net profit by half year, a loss in red
The half years either side of a change of basis do not compare. From the half year to Mar 2026, the company's revenue for the year to Mar 2026, ₹101 Cr, differs from its half years added, ₹97 Cr.
| ₹ crore | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 39.7 | 37.7 | 51.6 | 52.2 | 52.6 | 44.4 | 37.0 | 60.1 |
| Net profit | 1.0 | 1.3 | 1.7 | 2.5 | 1.9 | 6.1 | 2.4 | 3.3 |
| Net margin | 2.6% | 3.4% | 3.4% | 4.9% | 3.6% | 13.8% | 6.6% | 5.5% |
Consolidated. The 8 half years from Sep 2022, the first on record. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Year to Mar 2026, against the year before
- Revenue
- ₹101 Cr
- Net profitNet profit. The pill is the change in net profit against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹5.77 Crdown 28.16%
- Net margin
- 5.7%
Revenue by year
Net profit by year, a loss in red
The years either side of a change of basis do not compare. From the year to Mar 2026, the company's revenue for that year, ₹101 Cr, differs from its half years added, ₹97 Cr.
| ₹ crore | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Revenue | 77 | 104 | 97 | 101 |
| Net profit | 2 | 4 | 8 | 6 |
| Net margin | 3.0% | 4.1% | 8.3% | 5.7% |
Consolidated. Years to March. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Business segments
In the year to Mar 2026 the company reports one business segment, Manufacturing of of a wide range of Pharmaceutical products, which carries all its revenue.
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −7.8% | −28.1% | +28.0% | 0.2% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add.
Sotac Pharmaceuticals competitors and peers
Pharmaceuticals, 215 listed companies, priced on 28 Oct 2026. The table lists the 8 companies closest to Sotac Pharmaceuticals in market cap.Healthcare companies
Where the company sits among the companies nearest its size
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Godavari DrugsGODAVARI | 123 | 29.47 | 1.62 | +4.8% | +9.7% | 7.0% | 4.9% | 0.00% |
 Speciality MedicinesSPML | 119 | 9.17 | 1.68 | – | – | 18.3% | – | 0.00% |
 Parnax LabPARNAXLAB | 119 | 13.27 | 1.25 | +31.9% | −17.3% | 10.0% | 9.3% | 0.00% |
 BALAXI PHARMACEUTICALSBALAXI | 112 | 46.30 | 0.45 | −5.9% | −87.2% | 1.0% | 2.1% | 0.00% |
 Makers LaboratoriesMAKERSL | 112 | 32.65 | 1.53 | +17.6% | −61.6% | 4.8% | 11.1% | 0.00% |
 Alpa LaboratoriesALPA | 110 | – | 0.59 | +0.5% | – | – | −1.8% | 0.00% |
 Tyche IndustriesTYCHE | 105 | 23.46 | 0.74 | −21.0% | −63.5% | 3.2% | −2.5% | 3.43% |
| Himalaya Nutravedics IndiaHNIL | 101 | – | – | – | – | – | – | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Dividends
Per share, by the year it was paid for, and the latest payments.Sotac Pharmaceuticals dividend history
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up. Dividend per share in the glossaryHighest ₹0.20 a share, year to Mar 2026.
| Ex-date | Type | Per share |
|---|---|---|
| 23 Sep 2026 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. Final dividend in the glossary | ₹0.20 |
| 19 Sep 2025 | Final | ₹0.10 |
Latest payments, as declared, by ex-date.
Latest announcements
Routine notices left out.Sotac Pharmaceuticals announcements
Oct 2026
8 Oct · Board meeting
Sep 2026
30 Sep · Meeting
8 Sep · General Updates
8 Sep · Corporate action
Sotac Pharmaceuticals share price by year
Each calendar year to 2025.Sotac Pharmaceuticals share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 123.10 | +12.6% | 150.00 | 92.35 |
| 2024 | 109.30 | −7.4% | 189.05 | 103.10 |
| 2023 | 118.00 | – | 140.25 | 111.15 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. 2023 is from its first session, 13 Apr 2023.
Recent sessions
The 9 trading days to 27 Oct 2026, as traded on NSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 27 Oct 2026 | 93.00 | 96.50 | 93.00 | 96.50 | 94.75 | 2,400 | 100.0% |
| 21 Oct 2026 | 92.00 | 92.00 | 92.00 | 92.00 | 92.00 | 1,200 | 100.0% |
| 1 Oct 2026 | 90.05 | 90.05 | 90.05 | 90.05 | 90.05 | 1,200 | 100.0% |
| 20 Aug 2026 | 90.05 | 90.05 | 90.05 | 90.05 | 90.05 | 1,200 | – |
| 13 Aug 2026 | 87.40 | 87.40 | 87.40 | 87.40 | 87.40 | 1,200 | – |
| 31 Jul 2026 | 86.00 | 94.90 | 86.00 | 91.95 | 91.93 | 3,600 | – |
| 29 Jul 2026 | 90.40 | 90.40 | 90.40 | 90.40 | 90.40 | 1,200 | – |
| 15 Jul 2026 | 95.10 | 95.10 | 95.10 | 95.10 | 95.10 | 2,400 | – |
| 13 Jul 2026 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 1,200 | – |
Prices in ₹ per share as traded, not adjusted.
Company details
- NSE symbol
- SOTAC
- ISIN
- INE0O2D01012
- Industry
- Pharmaceuticals & Biotechnology